Peptide Tracker
← Library

Small molecule

5-Amino-1MQ

Preclinical NNMT inhibitor (small molecule)

50MG
Dose
50U
Draw
28D
Cycle

5-amino-1MQ is a small-molecule NNMT inhibitor studied only in mice, rats and cells. There is no human trial and no human dose. Figures below are community practice, not from a label or trial.

PTSEALED5-Amino-1MQ100 MGLYOPHILIZED
Sign in to start this protocolSign in to mix a vial

Protocols

  • Community metabolic blockrecommended

    Community practice, not from a label or trial: lowest end of the oral 50-150 mg/day range, shortest cycle (4 weeks).

Dosing

  • Community practice, not from a label or trial: oral 50-150 mg/day, usually in the morning, in 4-8 week cycles with a 1-2 week break.
  • Community practice, not from a label or trial: subcutaneous figures range from 150 mcg to 100 mg/day (about 40-fold spread, no reference); microgram doses are widely reported as ineffective.
  • Mouse study: once daily for 28 days (subcutaneous exposure data at 25 mg/kg); a human dose cannot be derived from this.

Route & timing

Route: Oral is the only route with (rat) pharmacokinetic support per Outliyr; subcutaneous injection is community use.

Timing: Community: morning; split AM/midday doses are common because the half-life is short.

Reconstitution

  • Not applicable to the oral form. The vial water in the protocol is arithmetic for an injectable community vial (100 mg + 1 mL gives 50 mg = 50 units), not a sourced instruction.

Reconstitution calculator

Concentration
100 mg/mL
Per unit
1 mg
Draw
50 units
Volume
0.5 mL
Doses per vial
2
Vials for cycle (28 doses), pooled
14
Vials, discard remainder
14
concentration = 100 / 1 = 100 mg/mL
per unit = 100 / 100 = 1 mg
units = 50 / 1 = 50
mL = 50 / 100 = 0.5
doses per vial = 100 / 50 = 2
pooled vials = ceil(50 x 28 / 100) = 14
discard vials = ceil(28 / floor(2)) = 14

Stability

No reliable figure found in the sources; ask your prescriber or supplier.

Off-cycle

1-2 weeks off after a 4-8 week cycle (community, oral).

Why:

  • Community reports describe effects fading after about 4-6 weeks; not evidence-based.

Stacking rules

  • Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
  • Additive stimulation with caffeine (community page).

Safety

Unapproved research chemical, not a lawful supplement. WADA-banned (S0) per Outliyr. No human safety data; genotoxicity unconfirmed.

Common side effects:

  • Anecdotal: sleep disruption, jitteriness, early anxiety, mild stomach upset, orange urine, tiredness after stopping.

Stop and call your prescriber if:

  • Palpitations
  • Severe anxiety
  • Blood pressure spikes
  • Persistent insomnia
  • Injection-site infection

Labs and monitoring:

  • Consider HbA1c, fasting insulin, lipid panel, homocysteine and ALT/AST before starting (Outliyr).

Markers to track

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

Sources

5-Amino-1MQ